On Demand Webinar

CVD Risk Prediction The Evolving Role of Laboratory Testing

  • Duration: 60 minutes
  • Date:SEP.18.2014 2:00 PM - 03:00 PM

Price: $69.00

Member Price: $59.00

This is a recorded version of an AACC live webinar that was held September 18, 2014. Cholesterol management and cardiovascular disease (CVD) risk assessment guidelines released in late 2013 by the American Heart Association (AHA) and the American College of Cardiology (ACC) have had a significant impact on the way clinicians approach CVD risk assessment and manage statin therapy. Patients on statin medicines, which are now prescribed for a quarter of Americans over 40, no longer need to lower their LDL cholesterol concentrations to specific numerical targets, they will just continue to take them as long as they are considered to be at risk for CVD. In order to determine a patient's risk, the 2013 guidelines recommend using a new risk calculator that also counts strokes as well as heart attacks in its risk calculations, a step that will probably make some additional people candidates for statin therapy.

What does this mean for clinical labs? Order this webinar and know:

  • How the new risk calculator differs from traditional risk prediction models such as the Framingham Risk Score
  • Current thinking on the most effective way to assess a patient?s CVD risk
  • How lipid assays and markers of inflammation are expected to be used in CVD risk assessment now and in the future
  • What the guidelines recommend regarding the use of statins to lower CVD risk

A Q&A session from the live webinar is also included on the recording.